Language interpretation solutions for breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates different language interpretation methods for Spanish- and Mandarin-speaking breast cancer patients with limited English proficiency during outpatient clinical encounters. It consists of two phases: the first is a randomized controlled trial comparing remote simultaneous and consecutive interpreting methods, while the second phase involves a mixed-methods evaluation to assess the implementation of these solutions. The goal is to improve communication between patients and healthcare providers, enhancing the overall care experience.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Phase I Patients

* Age \>=18 years (per EMR)
* Preferred language for healthcare is Spanish or Mandarin (per self-report)
* Limited English Proficient; cannot speak English "very well" (per self-report)
* Diagnosis of breast cancer or gastrointestinal (per EMR)
* Will be visiting MSK oncology teams for the first or second appointment (per EMR)
* Agrees to be audio-recorded (per self-report)

Phase 1 Providers

* Breast or gastrointestinal cancer provider who sees patients (e.g., breast or gastrointestinal oncologists, advanced practice providers, and/or nurses)
* Does not speak Spanish and/or Mandarin; providers who speak one language and not the other may participate (e.g., speaks Spanish but not Mandarin) (per self-report)
* Agrees to be audio-record (per self-report) Phase 2 (clinic staff only; patient participants will be drawn from Phase 1)
* Is a staff member who works/worked in one of the study clinic sites during the period of Phase 1 RCT study activities
* Agrees to be audio-recorded (per self-report)

Exclusion Criteria:

Phase 1 Patients

* Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team)
* Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team)

Phase I Providers

* None

Phase 2 (clinic staff only; Phase 1 patient participants follow above criteria)

* None

Where it's running

• Memorial Sloan Kettering Basking Ridge (Consent Only)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Consent Only)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Consent Only)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk- Commack (Consent Only)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Consent Only)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering at Ralph Lauren Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Francesca Gany, MD, MS — Memorial Sloan Kettering Cancer Center
• Study coordinator: Francesca Gany, MD, MS
• Email: ganyf@mskcc.org
• Phone: 646-888-8054

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer

  This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07188246

• Memantine plus structured exercise to protect thinking and memory during breast cancer chemotherapy

  This will test whether memantine combined with a supervised exercise program, memantine alone, or a placebo can prevent or reduce thinking and memory problems in people receiving chemotherapy for stage I–III breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06727773

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

• Evaluating skin reactions in breast cancer patients receiving proton therapy

  This study is testing a new technique to see if it can help reduce skin reactions in breast cancer patients getting proton therapy.

  Recruiting Covenant Health Cancer Center · Knoxville, Tennessee · NCT06006806

• Combining chemotherapy and radiation for high-risk breast cancer patients

  This study tests whether combining chemotherapy and radiation can help high-risk breast cancer patients who still have cancer after initial treatment, while also looking at how this treatment affects their immune system.

  Recruiting Phase 2/3 University of Virginia · Charlottesville, Virginia · NCT05288777

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.